PE20190178A1 - Constructos de alfavirus vivo atenuado y metodos y usos de los mismos - Google Patents

Constructos de alfavirus vivo atenuado y metodos y usos de los mismos

Info

Publication number
PE20190178A1
PE20190178A1 PE2018001927A PE2018001927A PE20190178A1 PE 20190178 A1 PE20190178 A1 PE 20190178A1 PE 2018001927 A PE2018001927 A PE 2018001927A PE 2018001927 A PE2018001927 A PE 2018001927A PE 20190178 A1 PE20190178 A1 PE 20190178A1
Authority
PE
Peru
Prior art keywords
alphavirus
ires
live attenuated
alfavirus
constructs
Prior art date
Application number
PE2018001927A
Other languages
English (en)
Inventor
Jill A Livengood
Timothy Duane Powell
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of PE20190178A1 publication Critical patent/PE20190178A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a un alfavirus recombinante vivo atenuado que comprende un acido nucleico de alfavirus que tiene un promotor subgenomico inactivado y una insercion de un sitio de entrada ribosomico interno (IRES) entre un extremo de la secuencia codificante de la proteina no estructural 4 (nsP4) y AUG de iniciacion de una secuencia codifcante de ARN subgenomico del alfavirus, donde al menos un IRES de virus comprende IRES de picornavirus tipo I o tipo II u otra secuencia de IRES capaz de producir un alfavirus vivo atenuado viable. Dichos alfavirus vivos atenuados son incapaces de replicarse en celulas de mosquitos y de transmision por mosquitos vectores
PE2018001927A 2016-03-31 2017-03-28 Constructos de alfavirus vivo atenuado y metodos y usos de los mismos PE20190178A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316264P 2016-03-31 2016-03-31
PCT/US2017/024450 WO2017172698A1 (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Publications (1)

Publication Number Publication Date
PE20190178A1 true PE20190178A1 (es) 2019-02-01

Family

ID=58501809

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001927A PE20190178A1 (es) 2016-03-31 2017-03-28 Constructos de alfavirus vivo atenuado y metodos y usos de los mismos

Country Status (17)

Country Link
US (1) US20190106682A1 (es)
EP (1) EP3436062A1 (es)
JP (1) JP2019509750A (es)
KR (1) KR20180135913A (es)
CN (1) CN109195625A (es)
AU (1) AU2017241669A1 (es)
BR (1) BR112018069079A2 (es)
CA (1) CA3019536A1 (es)
CO (1) CO2018010359A2 (es)
CR (1) CR20180457A (es)
DO (1) DOP2018000209A (es)
EC (1) ECSP18081582A (es)
MX (1) MX2018011839A (es)
PE (1) PE20190178A1 (es)
PH (1) PH12018502120A1 (es)
SG (1) SG11201808479VA (es)
WO (1) WO2017172698A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013236A (es) 2018-06-06 2021-02-22 Massachusetts Inst Technology Acido ribonucleico (arn) circular para traduccion en celulas eucariotas.
CN110213711B (zh) * 2019-04-22 2021-06-18 腾讯科技（深圳）有限公司 一种常驻点的估计方法、装置、设备和介质
CN114561366B (zh) * 2022-03-30 2023-06-20 西南民族大学 一种山羊库布病毒分离株及其应用
CN117925540B (zh) * 2024-03-22 2024-06-18 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
CN118127077A (zh) * 2024-05-08 2024-06-04 南京农业大学三亚研究院 基于盖塔病毒骨架的嵌合甲病毒制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
SG187513A1 (en) * 2008-01-24 2013-02-28 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Also Published As

Publication number Publication date
PH12018502120A1 (en) 2019-07-15
AU2017241669A1 (en) 2018-11-22
CO2018010359A2 (es) 2018-12-14
WO2017172698A1 (en) 2017-10-05
KR20180135913A (ko) 2018-12-21
JP2019509750A (ja) 2019-04-11
CN109195625A (zh) 2019-01-11
SG11201808479VA (en) 2018-10-30
BR112018069079A2 (pt) 2019-01-29
US20190106682A1 (en) 2019-04-11
CA3019536A1 (en) 2017-10-05
MX2018011839A (es) 2019-05-23
EP3436062A1 (en) 2019-02-06
ECSP18081582A (es) 2019-02-28
CR20180457A (es) 2019-04-09
DOP2018000209A (es) 2019-01-31

Similar Documents

Publication Publication Date Title
PE20190178A1 (es) Constructos de alfavirus vivo atenuado y metodos y usos de los mismos
CO2018005258A2 (es) Vacuna del virus herpes simple
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
CO2018005265A2 (es) Vacunas de ácido nucleico para el virus varicela-zóster
CL2018000587A1 (es) Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)
CO2021006362A2 (es) Construcciones de ácido nucleico y métodos de uso
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
CL2019002805A1 (es) Expresión selectiva de un transgene de tejidos.
CO2018006706A2 (es) Virus mutados, método de preparación y uso de los mismos
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
NZ587502A (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
WO2017156511A8 (en) Live attenuated zika virus vaccine
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
CL2021003328A1 (es) Composiciones que comprenden iga secretora y probióticos.
WO2012065105A3 (en) Chimeric flavivirus vaccines
CL2017002263A1 (es) Arn polimeriza ii33 moléculas de ácido nucleico para controlar plaga de insectos.
MY189334A (en) Lentiviral vector-based japanese encephalitis immunogenic composition
MX2019008668A (es) Transmisor y metodo de repeticion del mismo.
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
AR079970A1 (es) Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas
BR112019008584A2 (pt) vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a
AR119078A2 (es) Polinucleótido recombinante aislado; célula vegetal transgénica aislada, incapaz de generar un individuo completo; construcción de adn aislada; composición agrícola; y método para controlar una población de plagas de insectos
EA202191862A2 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
CL2018002333A1 (es) Virus recombinante de la enfermedad de newcastle que expresa una proteína inmunomoduladora como adyuvante molecular.